Technology | Thrombectomy Devices | July 25, 2019

Penumbra Launches Jet 7 Reperfusion Catheter With Xtra Flex Technology in U.S.

Catheter is used with Penumbra Engine in fully integrated Penumbra System for aspiration-based mechanical thrombectomy

Penumbra Launches Jet 7 Reperfusion Catheter With Xtra Flex Technology in U.S.

July 25, 2019 — Penumbra announced U.S. commercial availability of the Penumbra System’s most advanced technology, the Penumbra Jet 7 Reperfusion Catheter with Xtra Flex technology, at the Society of NeuroInterventional Surgery (SNIS) 16th Annual Meeting, July 22-25 in Miami. Penumbra Jet 7 with Xtra Flex technology is used with the Penumbra Engine in the fully integrated Penumbra System – an aspiration-based mechanical thrombectomy system that enables physicians to extract thrombus in acute ischemic stroke patients.

The Penumbra System is a fully integrated system designed specifically for mechanical thrombectomy by aspiration that first received 510(k) clearance by the U.S. Food & Drug Administration (FDA) in December 2007. It enables physicians to use aspiration, which acts like a minimally invasive “vacuum” inside the artery to remove stroke-causing blood clots from the brain safely and effectively. It is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusion.

The Penumbra Jet 7 Reperfusion Catheter with Xtra Flex technology is the latest advancement in the Penumbra System Jet – Engine family of products, which was launched last September.  As the eighth-generation reperfusion catheter for proximal large vessel occlusions, the catheter is designed for advanced trackability and navigation, and maintains the large 0.072-inch lumen.  Penumbra Jet 7 with Xtra Flex technology together with the power of the Penumbra Engine are designed to maximize thrombus removal force.

Initial clinical experience with the new technology was shared in the Industry Technology Luncheon Symposium by Donald F. Frei, M.D., director of neuro-interventional surgery, Swedish Medical Center, Englewood, Colo. 

For more information: www.penumbrainc.com

Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init